To explore the potential utility of CDK4/6 inhibitors in gammaherpesvirus-induced tumors, we investigated the effect of the 3 approved CDK4/6 inhibitors, Abe, Pal, and Rib on the proliferation of PEL cells, of KSHV-infected human umbilical endothelial cells (HUVEC), and of EBV-infected BL cells. This evidence concerns the gene CDK4 and Burkitt lymphoma.